Asset Management, Lp Chen B... Net Worth

The estimated Net Worth of Asset Management, Lp Chen B... is at least $40.4 Million dollars as of 23 November 2020. Asset B owns over 425,000 units of Olema Pharmaceuticals stock worth over $40,358,513 and over the last 4 years Asset sold OLMA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Asset B OLMA stock SEC Form 4 insiders trading

Asset has made over 1 trades of the Olema Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Asset bought 425,000 units of OLMA stock worth $8,075,000 on 23 November 2020.

The largest trade Asset's ever made was buying 425,000 units of Olema Pharmaceuticals stock on 23 November 2020 worth over $8,075,000. On average, Asset trades about 425,000 units every 0 days since 2020. As of 23 November 2020 Asset still owns at least 3,270,544 units of Olema Pharmaceuticals stock.

You can see the complete history of Asset B stock trades at the bottom of the page.

Insiders trading at Olema Pharmaceuticals

Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham und Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.

What does Olema Pharmaceuticals do?

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Complete history of Asset B stock trades at Olema Pharmaceuticals

Olema Pharmaceuticals executives and stock owners

Olema Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Sean P. Bohen M.D., Ph.D.,
  Pres, CEO & Director
• Dr. Cyrus L. Harmon Ph.D.,
  CTO & Director
• Dr. Sean P. Bohen,
  Pres, CEO & Director
• John B. Moriarty Jr.,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• Dr. Peter J. Kushner Ph.D.,
  Chief Scientific Officer
• Dr. Naseem Zojwalla M.D.,
  Chief Medical Officer
• Demiana Faltaos Ph.D., Pharm.D.,
  VP & Head of Clinical Pharmacology
• Dr. Leslie Hodges Gallagher Ph.D.,
  Sr. VP of Discovery Biology
• Kinney Horn,
  Chief Bus. Officer
• Dr. David C. Myles,
  Chief Devel. Officer
• Julie Dexter,
  VP & Head of People
• Eva Stroynowski,
  VP of Communications & Investor Relations
• Shane William Charles Kovacs M.B.A.,
  Chief Operating & Financial Officer
• J. Scott Garland,
  
• Frank Mccormick,
  Director
• Andrew Rappaport,
  
• Biomedical Innovation Maste...,
  10% owner
• Asset Management, Lp Chen B...,
  
• Partners L P/Ilbiotechnolog...,
  
• Ian T Clark,
  
• Gorjan Hrustanovic,
  
• Sean Bohen,
  PRESIDENT AND CEO
• Cynthia M Butitta,
  
• David C. Myles,
  CH. DISCOV. & NON-CLIN DEV OFF
• Yi Larson,
  
• Peter J. Kushner,
  CHIEF SCIENTIFIC OFFICER
• Shane William Charles Kovacs,
  CH. OPERATING & FINANCIAL OFF.
• Kinney Horn,
  Chief Business Officer
• Cyrus Harmon,
  
• John B Moriarty,
  EVP, Ch. Legal Officer & Sec.
• Biocapital Advisors Lp Para...,
  
• G. Walmsley Graham,
  
• Naseem Zojwalla,
  CHIEF MEDICAL OFFICER